FDA
-
-
-
-
-
-
-
FDA approves Outlook Therapeutics' Lytenava for wet AMD
-
-
-
-
-
-
-
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
-
-
-
-
-
-
Outlook Therapeutics raises $5 million in registered direct offering
-
-
-
-
-
-
-
Outlook Therapeutics closes $5 million public offering
-
-
-
-
-
-
-
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
-
-
-
-
-
-
-
Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinks
-
-
-
-
-
-
-
Outlook Therapeutics resubmits drug application to FDA after September meeting
-
328,512 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

